Close Menu
Skip to main content
GenomeWeb
360Dx
Precision Oncology News
Precision Oncology News
*
*
Show password
Forgot your password?
Subscribe
Contains all of these words:
You may find more results for this query on our sister sites:
GenomeWeb
and
360Dx
.
Business & Policy
Business News
Regulatory News
Reimbursement
Biomarkers
BRCA
EGFR
HER2
KRAS
BRAF
ROS1
ALK
PD-L1
Cancer Specialties
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Brain Cancer
Melanoma
Pediatric Cancer
Oncology Trends
Next-Generation Sequencing
Minimal Residual Disease
Microsatellite Instability Testing
Immunotherapy
Liquid Biopsy
Resources
Webinars
White Papers
Conferences & Events
Partner Content
Menu
Home
›
About Us
›
Our Staff
›
Miriam Munn
Miriam Munn
Premium Content Account Manager
Phone Number
+1-212-651-5612
Email
[email protected]
Breaking
News
Calithera Biosciences Begins Phase II Lung Cancer Trial of Telaglenastat Plus Chemo, Immunotherapy
Ideaya, Pfizer Expand Collaboration to Study IDE196, Xalkori
Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature
FDA Accepts Pfizer's sNDA for Xalkori in Rare ALK-Positive Pediatric Leukemia Indication
Novellus Raises $57M in Series C Funding
Metastatic Cancer Treatment Markers Identified in Clinical WGS Study
Sign Up for Topical Newsletters
